Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo
Patents for A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
10/2003
10/07/2003US6630125 Use as imaging agents (for example, as positron emission tomography imaging agents); noninvasive detection and localization of neoplasms influencing choline processing in the body
10/07/2003US6630123 Method to enhance tissue accumulation of radiolabeled compounds
10/07/2003US6629988 Composite staple for completing an anastomosis
10/02/2003WO2003080554A2 Iodinated triglyceride analogs
10/02/2003WO2003080171A1 Intraductal management of breast lesions involving therapeutic or diagnostic agents
10/02/2003WO2003061577A3 Polyalkylene glycol with moiety for conjugating biologically active compound
10/02/2003WO2003010199A3 Identification of specific tumour antigens by means of the selection of cdna libraries with sera and the use of said antigens in diagnostic imaging techniques
10/02/2003US20030187247 Immunoglobulin for use in prevention and treatment of viral diseases; immunotheray; immunoassay
10/02/2003US20030186930 Uridine analogs and techniques for making and using
10/02/2003US20030186384 Comprises enzyme complex formed from proteases for modulating apoptosis and treating tumor, allergenic, autoimmune diseases and inflammatory diseases
10/02/2003US20030185895 Spherical polymer particle (e.g., a polyvinyl acetal) having an internal reservoir region including large pores containing therapeutic agent and a metering region having fewer relatively large pores.
10/02/2003US20030185832 Administering a targeting agent operatively attached to a therapeutic agent; the targeting agent recognizes and binds to a tumor-associated endothelial cell marker.
10/02/2003US20030185810 Tumor radiosensitization using gene therapy
10/02/2003US20030185793 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
10/02/2003CA2478330A1 Intraductal management of breast lesions involving therapeutic or diagnostic agents
10/01/2003EP1348026A2 Fibrin binding moieties useful as imaging agents
10/01/2003EP1347982A2 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
10/01/2003EP1347784A2 Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
10/01/2003EP1347711A1 Method and apparatus for therapeutic emr treatment of the skin
10/01/2003CN1446229A Somatostatin analogues
10/01/2003CN1446197A Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
10/01/2003CN1446104A Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
09/2003
09/30/2003US6627215 Devices for improved wound management
09/30/2003US6627176 Therapy; diagnosis
09/25/2003WO2003078393A2 Fluorinated phenyl thiophenyl derivatives and their use for imaging serotonin transporters
09/25/2003WO2003077871A2 Method of diagnosis and treatment of breast lesions
09/25/2003WO2003077727A2 Technetium-dipyridine complexes, and methods of use thereof
09/25/2003WO2003077723A2 Methods and devices for detection and therapy of atheromatous plaque
09/25/2003WO2003020945A3 An enzymatic process for the synthesis of organo-fluorine compounds
09/25/2003WO2002062819A3 Backbone cyclized radiolabelled somatostatin analogs
09/25/2003WO2002055688A8 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
09/25/2003US20030180817 Determining levels of a colon specific gene in the cells, or bodily fluids in a patient, comparing determined levels of CSG with levels of CSG in cells from normal human control, wherein a change in level of CSG indicates presence of cancer
09/25/2003US20030180710 Using an isotope such as a stable (13C) isotope for labeling a metabolome to examine mechanisms of cellular substrate flow modification in response to various drugs, which can improve the drug discovery and testing processes
09/25/2003US20030180305 Pharmaceuticals for the imaging of angiogenic disorders
09/25/2003US20030180295 Angiocidin: a Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor
09/25/2003US20030180223 Diagnostic imaging contrast agents with extended blood retention
09/25/2003CA2478248A1 Methods and devices for detection and therapy of atheromatous plaque
09/25/2003CA2477828A1 Method of diagnosis and treatment of breast lesions
09/24/2003EP1346730A1 Pretargeting methods and novel pretargeting conjugates
09/24/2003EP1345968A2 Crystals of whole antibodies and fragments thereof and methods for making and using them
09/24/2003EP1345630A1 Stabilised radiopharmaceutical compositions
09/23/2003US6624169 Urokinase inhibitors
09/18/2003WO2003076565A2 Methods of using 46828, a human acyl-coa synthetase
09/18/2003WO2003076469A2 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
09/18/2003WO2003076461A2 Dimeric tf antagonist comprising two factor vii polypeptides
09/18/2003WO2003075960A1 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
09/18/2003WO2003053509A3 Radioactive ion
09/18/2003WO2002100479A3 Radioactive medical devices and methods of making radioactive medical devices
09/18/2003WO2002092136A3 Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy
09/18/2003US20030176784 Labeling targeting agents with gallium-68 and gallium-67
09/18/2003US20030176670 Multivalent macrolide antibiotics
09/18/2003US20030176663 Specific binding molecules for scintigraphy
09/18/2003US20030176389 Administering to a subject suffering from gastrointestinal inflammation a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-CpG-3'
09/18/2003US20030176320 For therapy of cancer, autoimmune diseases and restenosis; efficiency
09/18/2003US20030175289 TIE ligands
09/18/2003US20030175209 Image diagnosis of a brain tumor, renal carcinoma; tumor treatment therapies, immunotherapy
09/18/2003US20030175206 Administering large liposomes to retend radioactive decay intermediates
09/18/2003US20030175205 Comprising a radioactive materials for detecting and/or quantifying diseases or conditions associated with cancer, infections, inflammation; a 2-propane carboxylic ester with a attached phosphatidic acid group
09/17/2003EP1343820A1 Human anti-epidermal growth factor receptor single-chain antibodies
09/17/2003EP1343534A2 Treatment of cancer with positron-emitting radiopharmaceuticals
09/17/2003EP1343498A1 Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders
09/17/2003EP1091763B1 Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters
09/17/2003EP1003560B1 Radioprotectant for peptides labeled with radioisotope
09/17/2003EP0804439B1 Beta, beta '-dihydroxy meso-substituted chlorins, isobacteriochlorins, bacteriochlorins, and methods for making the same from beta ,beta '-unsubstituted tetrapyrrolic macrocycles
09/16/2003US6620781 Glycopeptide carboxy-saccharide derivatives
09/12/2003WO2003074992A2 Phosphorylated proteins and uses related thereto
09/12/2003WO2003074569A2 Bispecific antibody point mutations for enhancing rate of clearance
09/12/2003WO2003074568A1 Individualized anti-cancer antibodies
09/12/2003WO2003074519A1 Coumarines useful as biomarkers
09/12/2003WO2003074450A2 Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
09/12/2003WO2003074005A2 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
09/12/2003WO2003045940A3 Benzazepine derivatives and their use as 5-ht ligands
09/12/2003WO2002085418A3 Tc and re labeler radioactive glycosylated octreotide derivatives
09/12/2003WO2002082041A3 Production and use of novel peptide-based agents for use with bi-specific antibodies
09/12/2003WO2002072830A3 Proteins associated with cell growth, differentiation, and death
09/12/2003WO2002017969A9 Reagents and methods for the diagnosis of cmv dissemination
09/12/2003CA2666005A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
09/12/2003CA2478047A1 Rs7 antibodies
09/12/2003CA2478011A1 Bispecific antibody point mutations for enhancing rate of clearance
09/12/2003CA2477836A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
09/12/2003CA2472298A1 Coumarines useful as biomarkers
09/12/2003CA2456077A1 Individualized anti-cancer antibodies
09/11/2003WO2003074566A2 Rs7 antibodies
09/11/2003US20030171687 Reagent and method for measuring lung function
09/11/2003US20030171638 Method for manufacturing radioactive brachytherapy source material, brachytherapy source material and encapsulated radioactive brachytherapy source
09/11/2003US20030171561 Aminocarboxylate ligands having substituted aromatic amide moieties
09/11/2003US20030171548 Immunoreactive proteins where the percentage of immuno-reactive molecules as determined in a modified Lindmo-test is >81%; fermentation of culture of fluidized reactor; diagnosis of inflammatory and bone marrow displacing process
09/11/2003US20030170697 Detection and treatment of infections with immunoconjugates
09/11/2003US20030170299 Therapeutic methods for acute myeloid leukemia
09/11/2003US20030170297 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
09/11/2003US20030170286 Codrug with at least two constituent moieties cleavably linked covalently to one another; dimensioned to position two radiation seeds a predetermined distance apart.
09/11/2003US20030170222 For therapy of cancer; for therapy of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors
09/11/2003US20030170175 Cytotoxic therapy
09/11/2003US20030170174 For therapy of diseases, such as parasitic and viral infections, conditions associated with inflammation and infection, and conditions mediated by cell-proliferation or collagen formation; contrast agents
09/11/2003US20030170173 Contrast agents
09/10/2003EP1341559A2 Radioactive seed with multiple markers and method for using same
09/10/2003EP1109583B1 Method and device for delivery of therapeutic agents in conjuction with isotope seed placement
09/10/2003EP0993306B1 Perfluoroalkylated oligomer compounds, process for preparing the same and their use in nmr diagnosis
09/10/2003EP0946202B1 Contrast agents
09/10/2003EP0873139B1 Biotinylated antibodies with reduced net positive charge and toxin, drug or chelate
1 ... 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 ... 243